Skip to content

Price / sales at other companies

Gilead Sciences logo
Gilead SciencesGILD
5.8×+1.0×
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
27.3×+2.9×
Arrowhead Research logo
Arrowhead ResearchARWR
14.1×+10.9×
LQD
Liquidia CorporationLQDA
11.5×-77.4×
Alkermes logo
AlkermesALKS
3.8×+0.2×
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
11.7×+5.0×

Other financials

Income statement

See full
Revenue$159.9M+43.3%
Operating income-$789.5M-5,100%
Net income-$790.2M-5,284%
EPS (diluted)-$13.43-4,377%

Balance sheet

See full
Cash & equivalents$261.5M+43.5%
Total debt$13.5M+56.4%
Total equity$242.5M+4.0%
Total assets$890.9M+29.1%

Cash flow

See full
Operating cash flow-$228.8M-11,566%
CapEx$664.0K+1,520%
Free cash flow-$229.4M-11,360%

Valuation

See full
Market cap$6.53B+152%
Enterprise value$6.28B+162%

Profitability

See full
Operating margin-139.8%-168pp
Net margin-140.2%-169pp
FCF margin-30.3%

Returns & leverage

See full
Return on equity-335.8%-377pp
Debt / equity0.1×0.0×
Current ratio2.1×-1.1×

Where this comes from

Calculated from Mirum Pharmaceuticals, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mirum Pharmaceuticals, Inc.'s price / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mirum Pharmaceuticals, Inc.'s price / sales?
Mirum Pharmaceuticals, Inc. (MIRM) reported price / sales of 9.8× in Q1 2026.
How has Mirum Pharmaceuticals, Inc.'s price / sales changed year-over-year?
Mirum Pharmaceuticals, Inc.'s price / sales increased by 68.1% year-over-year, from 5.8× to 9.8×.
What is the long-term trend for Mirum Pharmaceuticals, Inc.'s price / sales?
Over 4 years (2021 to 2025), Mirum Pharmaceuticals, Inc.'s price / sales has grown at a -25.6% compound annual growth rate (CAGR), from 25.5× to 7.8×.
What does price / sales mean?
Market capitalization at the quarter end divided by trailing-twelve-month revenue. The price the market pays for each dollar of sales.